Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT Abstract #1341

Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.
Aim(s): To investigate the influence of lanreotide on the uptake of [68Ga]-DOTATATE in tumor- and normal tissue.
Materials and methods: 34 patients with metastatic/unresectable NET being treated with lanreotide and scheduled for [68Ga]-DOTATATE PET/CT are included. The PET/CT scan is made on the day before and the day after lanreotide injection in each patient. [68Ga]-DOTATATE uptake in the primary tumor, metastases, and normal tissue are quantified (SUVmax, mean, peak).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Else Aalbersberg
Keywords: DOTATATE

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result